8.92
-0.14 (-1.55%)
| Previous Close | 9.06 |
| Open | 9.09 |
| Volume | 3,468,969 |
| Avg. Volume (3M) | 4,851,630 |
| Market Cap | 2,267,130,880 |
| Price / Earnings (Forward) | 78.74 |
| Price / Sales | 2.30 |
| 52 Weeks Range | |
| Earnings Date | 3 Aug 2026 |
| Profit Margin | -10.62% |
| Operating Margin (TTM) | 14.59% |
| Diluted EPS (TTM) | -0.260 |
| Quarterly Revenue Growth (YOY) | 56.90% |
| Current Ratio (MRQ) | 2.93 |
| Operating Cash Flow (TTM) | -25.85 M |
| Levered Free Cash Flow (TTM) | 42.90 M |
| Return on Assets (TTM) | 4.54% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - Specialty & Generic (US) | Mixed | Bullish |
| Drug Manufacturers - Specialty & Generic (Global) | Mixed | Bullish | |
| Stock | BioCryst Pharmaceuticals, Inc. | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | -2.0 |
| Insider Activity | 1.5 |
| Price Volatility | -2.0 |
| Technical Moving Averages | 1.5 |
| Technical Oscillators | 2.0 |
| Average | 0.20 |
|
BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Investment Style | Small Growth |
| % Held by Insiders | 1.20% |
| % Held by Institutions | 87.44% |
No data within this time range.
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| FRANK STEVEN | 8.50 | - | 15,294 | 129,999 |
| GALSON STEVEN K | 8.50 | - | 15,294 | 129,999 |
| HEGGIE THERESA | 8.50 | - | 15,294 | 129,999 |
| LEVIN ALAN G | 8.50 | - | 15,294 | 129,999 |
| MCKEE AMY E | 8.50 | - | 15,294 | 129,999 |
| MILANO VINCENT | 8.50 | - | 15,294 | 129,999 |
| MILNE JILL C. | 8.50 | - | 15,294 | 129,999 |
| SANDERS MACHELLE | 8.50 | - | 15,294 | 129,999 |
| STONEHOUSE JON P | 8.50 | - | 15,294 | 129,999 |
| Aggregate Net Quantity | 137,646 | |||
| Aggregate Net Value ($) | 1,169,991 | |||
| Aggregate Avg. Buy ($) | 8.50 | |||
| Aggregate Avg. Sell ($) | - | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| HEGGIE THERESA | Director | 11 Jun 2026 | Acquired (+) | 15,294 | 8.50 | 129,999 |
| MCKEE AMY E | Director | 11 Jun 2026 | Acquired (+) | 15,294 | 8.50 | 129,999 |
| STONEHOUSE JON P | Director | 11 Jun 2026 | Acquired (+) | 15,294 | 8.50 | 129,999 |
| MILANO VINCENT | Director | 11 Jun 2026 | Acquired (+) | 15,294 | 8.50 | 129,999 |
| SANDERS MACHELLE | Director | 11 Jun 2026 | Acquired (+) | 15,294 | 8.50 | 129,999 |
| FRANK STEVEN | Director | 11 Jun 2026 | Acquired (+) | 15,294 | 8.50 | 129,999 |
| LEVIN ALAN G | Director | 11 Jun 2026 | Acquired (+) | 15,294 | 8.50 | 129,999 |
| GALSON STEVEN K | Director | 11 Jun 2026 | Acquired (+) | 15,294 | 8.50 | 129,999 |
| MILNE JILL C. | Director | 11 Jun 2026 | Acquired (+) | 15,294 | 8.50 | 129,999 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |